The European Laboratory Research & Innovation Group (ELRIG) UK, a not-for-profit, volunteer-led organization for the drug discovery community, today entered into a partnership with SRG, leaders in life science recruitment, to support the advancement of science professionals in their careers.
Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer
SAN FRANCISCO — Adding the novel anti-TIGIT monoclonal antibody tiragolumab plus atezolizumab (Tecentriq) to standard first-line chemotherapy significantly improved survival for patients with advanced esophageal